Publication:
Pazopanib-Induced Reversible Left Ventricular Systolic Dysfunction

Simple item page
dc.contributor.authorRoongsangmanoon W.
dc.contributor.authorWattanawinitchai K.
dc.contributor.authorCharonpongsuntorn C.
dc.contributor.authorChonmaitree P.
dc.contributor.authorWongsoasup A.
dc.contributor.authorRattanajaruskul N.
dc.contributor.authorAngkananard T.
dc.date.accessioned2022-12-14T03:17:36Z
dc.date.available2022-12-14T03:17:36Z
dc.date.issued2022
dc.date.issuedBE2565
dc.description.abstractPazopanib is a tyrosine kinase inhibitor used for the treatment of advanced renal cell carcinoma and advanced soft tissue sarcoma. The authors describe a patient with advanced renal cell carcinoma who developed severe hypertension and severe left ventricular systolic dysfunction after starting pazopanib therapy with subsequent recovery of left ventricular ejection fraction upon treatment interruption. © JOURNAL OF THE MEDICAL ASSOCIATION OF THAILAND
dc.format.mimetypeapplication/pdf
dc.identifier.citationJournal of the Medical Association of Thailand. Vol 105, No. (2022), p.S130-S133
dc.identifier.doi10.35755/jmedassocthai.2022.S01.00030
dc.identifier.issn1252208
dc.identifier.urihttps://hdl.handle.net/20.500.14740/10291
dc.language.isoeng
dc.rights.holderScopus
dc.subject.otherBisoprolol
dc.subject.otherFurosemide
dc.subject.otherHydralazine
dc.subject.otherIsosorbide dinitrate
dc.subject.otherLosartan
dc.subject.otherPazopanib
dc.subject.otherProtein tyrosine kinase inhibitor
dc.subject.otherSunitinib
dc.subject.otherTroponin
dc.subject.otherValsartan
dc.subject.otherAged
dc.titlePazopanib-Induced Reversible Left Ventricular Systolic Dysfunction
dc.typeArticle
dspace.entity.typePublication
swu.datasource.scopushttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85123318091&doi=10.35755%2fjmedassocthai.2022.S01.00030&partnerID=40&md5=0dc61225497cf3b9c8c93a9208cc471c

Files

Collections

Scopus: Year 2022